News and Announcements
Shivom’s Alpha Release set for November 15th
- Published November 05, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Shivom’s Alpha is set to be released on November 15th.
- The Alpha product showcases the companies unique selling points, the secure storage of DNA data.
Shivom are delighted to announce that their Alpha product is set to be released this month.
The official release date is forecast to be November 15th.
The team has been working tirelessly on the launch of the Alpha product which aims to showcase one of the companies USP’s – secure storage of DNA data.
The Alpha product enables individuals to control and access their genomic data.
Shivom is a blockchain-based genomics startup that creates an ecosystem for genomic services. Following the launch of Alpha, Shivom will be launching a new website inline with their OMIX platform.
Shivom launched their innovation series with episode 1, with David Orban, speaking about genetic therapies and personalised health with Shivom.
Upcoming Events for Shivom
- Malta Blockchain Summit at Malta Intercontinental – Nov 1 to Nov 2
- Smart Health at Raffles Dubai – Nov 13 to Nov 14
- SLUSH Small Talks at Hyderabad, India – Nov 22
- Digital Freedom Festival (TBC) at Riga, Latvia – Nov 30
About Shivom
Shivom combines blockchain, A.I., DNA sequencing & cryptography to enable secure and personalized medicine. The Shivom platform works on collaboration & integrity, allowing people to own, manage and monetize their data. By creating a web-marketplace, a network of genomic counsellors, and a not-for-profit drug research unit, Shivom will build a global healthcare ecosystem, reaching even low-income countries.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
